Attached files

file filename
EX-99.1 - EX-99.1 - Wright Medical Group N.V.a11-6125_4ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  March 1, 2011

 


 

Tornier N.V.

(Exact name of registrant as specified in its charter)

 

The Netherlands

(State or other jurisdiction of incorporation)

 

333-167370

(Commission File Number)

 

98-0509600

(IRS Employer Identification No.)

 


 

Fred Roeskestraat 123

1076 EE Amsterdam
(+ 31) 20 675 4002

(Address of principal executive offices and telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02               Results of Operations and Financial Condition.

 

On March 1, 2011, Tornier N.V. (the “Company”) issued a press release announcing its consolidated financial results for the fourth quarter and full fiscal year ended January 2, 2011.  A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

 

The attached press release includes the following non-GAAP measures: EBITDA, which represents net loss before interest expense, income tax benefit, depreciation and amortization, and Adjusted EBITDA, which gives further effect to, among other things, non-operating (expense) income related to the mark to market of the previously outstanding warrant liability, foreign currency gains and losses, special charges, share-based compensation and operating expenses from a consolidated variable interest entity.

 

In order to measure the Company’s sales performance on a constant currency basis, it is necessary to remove the impact of changes in foreign currency exchange rates, which affects the comparability and trend of sales.  Constant currency results are calculated by translating current year results at prior year average foreign currency exchange rates. 

 

The Company believes that EBITDA and Adjusted EBITDA provide additional information for measuring performance and are measures frequently used by securities analysts and investors and therefore management uses these metrics to evaluate the Company’s business.  EBITDA and Adjusted EBITDA do not represent, and should not be used as a substitute for, net income or cash flows from operations as determined in accordance with generally accepted accounting principles, and neither EBITDA nor Adjusted EBITDA is necessarily an indication of whether cash flow will be sufficient to fund the Company’s cash requirements.  The Company’s definitions of EBITDA and Adjusted EBITDA may differ from that of other companies.

 

In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.  The Company believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate its results of operations in conjunction with the corresponding GAAP measures.

 

The Company uses these non-GAAP measures in making operating decisions because it believes the measures provide meaningful supplemental information regarding core operational performance and give a better understanding of how the Company should invest in research and development activities and how the Company should allocate resources to both ongoing and prospective business initiatives.  The Company uses these measures to help make budgeting and spending decisions, for example, between product development expenses and research and development, sales and marketing and general and administrative expenses.  Additionally, management is evaluated on the basis of these non-GAAP measures when determining achievement of their incentive performance compensation targets.  Further, these non-GAAP measures facilitate management’s internal comparisons to both the Company’s historical operating results and to the Company’s competitors’ operating results.

 

2



 

All of the non-GAAP measures are reconciled to the most directly comparable GAAP measure in the press release.  The Company is furnishing the information contained in this report, including the Exhibit, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”).  This information shall not be deemed to be “filed” with the SEC or incorporated by reference into any other filing with the SEC.  By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report, including the Exhibit.

 

Item 9.01               Financial Statements and Exhibits.

 

(d)                                 Exhibits

 

The following exhibits are being filed with this Current Report on Form 8-K:

 

99.1                           Press Release dated March 1, 2011.

 

3



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 1, 2011

 

 

 

TORNIER N.V.

 

 

 

By:

/s/ Carmen L. Diersen

 

Name:

Carmen L. Diersen

 

Title:

Global Chief Financial Officer

 

4



 

EXHIBIT INDEX

 

Exhibit Number

 

Description

 

 

 

99.1

 

Press Release dated March 1, 2011.

 

5